Reinovax’s R&D center has a lab space of 2,200 square meters. It empowers the ability in various research technologies including gene engineering, cultivation and fermentation, separation and purification, bacterial polysaccharide technology, molecular coupling, immune evaluation, quality evaluation, adjuvant technology, and mRNA technology, which serves as a solid foundation for the R&D of novel vaccines and protein therapeutics.

A GMP-like pilot-scale manufacturing base with an area of 5,026 square meters was established in Lingang, Shanghai. The base encompasses pilot-scale process development, GMP-like pilot-scale manufacturing, filling system, QC laboratory, QA system, and various utility systems. It provides an indispensable platform for process optimization, IND application, and the preparation of clinical samples.

The commercial scale GMP manufacturing base located in Changchun city, compliant with WHO/EU standards, occupies a total area of approximately 78,700 square meters with the completed construction area of 77,600 square meters at the first stage. This site possesses the capacity of the complete GMP manufacturing from the cell bank to the finished product as well as the all supporting functional units such as quality system, utilities, warehouse, animal facility, waste management, and office building etc.